Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
BMC Cancer
    July 2025
  1. XU S, Song Z, Wang D, Wang E, et al
    Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS).
    BMC Cancer. 2025;25:1190.
    >> Share

  2. OU G, Gou J, Ou H, Zheng H, et al
    Gut markers for metastatic melanoma receiving immunotherapy.
    BMC Cancer. 2025;25:1083.
    >> Share

    May 2025
  3. LUCKETT T, Ng CA, Lai-Kwon J, Kee D, et al
    Uncertainty and hope in people with metastatic uveal melanoma in the era of immunotherapy and targeted treatments: a theory-based qualitative study.
    BMC Cancer. 2025;25:939.
    >> Share

  4. CHEN SH, Yu BY, Kuo WY, Lin YB, et al
    Unveiling the immune microenvironment of complex tissues and tumors in transcriptomics through a deconvolution approach.
    BMC Cancer. 2025;25.
    >> Share

    April 2025
  5. YE M, Ren S, Luo H, Wu X, et al
    Integration of graph neural networks and transcriptomics analysis identify key pathways and gene signature for immunotherapy response and prognosis of skin melanoma.
    BMC Cancer. 2025;25:648.
    >> Share

  6. ZHAO S, Li Z, Liu K, Wang G, et al
    Combining multi-omics analysis with machine learning to uncover novel molecular subtypes, prognostic markers, and insights into immunotherapy for melanoma.
    BMC Cancer. 2025;25:630.
    >> Share

  7. ZHAO W, Chen Z, Fu W, Ye C, et al
    Induction of apoptosis and hypoxic stress in malignant melanoma cells via graphene-mediated far-infrared radiation.
    BMC Cancer. 2025;25:620.
    >> Share

    March 2025
  8. MANGER I, Schmitt C, Berking C, French LE, et al
    Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study.
    BMC Cancer. 2025;25:565.
    >> Share

  9. MOLONEY M, Harris PM, Kaczmarski P, Zheng S, et al
    Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasound-guided superficial radiotherapy, a multi-institutional study.
    BMC Cancer. 2025;25:526.
    >> Share

    January 2025
  10. ZHOU L, Zhou Q, Guo Q, Lai P, et al
    Dual role of Cathepsin S in cutaneous melanoma: insights from mendelian randomization and bioinformatics analysis.
    BMC Cancer. 2025;25:104.
    >> Share

  11. NASERI H, Safaei AA
    Diagnosis and prognosis of melanoma from dermoscopy images using machine learning and deep learning: a systematic literature review.
    BMC Cancer. 2025;25:75.
    >> Share

  12. EVERATT R, Kuzmickiene I, Brasiuniene B, Vincerzevskiene I, et al
    Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.
    BMC Cancer. 2025;25:38.
    >> Share

    December 2024
  13. BORILOVA S, Grell P, Selingerova I, Gescheidtova L, et al
    Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer.
    BMC Cancer. 2024;24:1590.
    >> Share

  14. FARIAS RM, Jiang Y, Levy EJ, Hwang C, et al
    Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy.
    BMC Cancer. 2024;24:1493.
    >> Share

    November 2024
  15. ZHANG S, Zang L, Li Y, Pang Y, et al
    Numb and NumbL inhibit melanoma tumor growth by influencing the immune microenvironment.
    BMC Cancer. 2024;24:1419.
    >> Share

  16. CAI X, Lin J, Li C, Xu T, et al
    MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
    BMC Cancer. 2024;24:1384.
    >> Share

    October 2024
  17. FERRIER ST, Li M, Burnier JV
    Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell lines.
    BMC Cancer. 2024;24:1299.
    >> Share

  18. DI PIETRO FR, Marinelli D, Verkhovskaia S, Poti G, et al
    Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
    BMC Cancer. 2024;24:1220.
    >> Share

    August 2024
  19. YU H, Ding G, Gong Q, Ma J, et al
    Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion.
    BMC Cancer. 2024;24:1034.
    >> Share

    July 2024
  20. GARCIA AM, Parra-Lara LG, Mendoza-Urbano DM, Bravo JC, et al
    Survival of patients with mucosal melanoma in Cali, Colombia: a retrospective cohort study.
    BMC Cancer. 2024;24:886.
    >> Share

  21. YIN W, Li R, Zhang Z, Wang Y, et al
    Causal association between skin cancer and immune cells: mendelian randomization (MR) study.
    BMC Cancer. 2024;24:849.
    >> Share

  22. TONDER JE, Bonnelykke-Behrndtz ML, Laurberg T, Rossell EL, et al
    Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:812.
    >> Share

  23. DIDIER AJ, Nandwani SV, Watkins D, Fahoury AM, et al
    Patterns and trends in melanoma mortality in the United States, 1999-2020.
    BMC Cancer. 2024;24:790.
    >> Share

    June 2024
  24. GAULT A, Hogarth L, Williams KC, Greystoke A, et al
    Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.
    BMC Cancer. 2024;24:733.
    >> Share

    May 2024
  25. KAMMINGA NCW, van der Veldt AAM, Wakkee M, van den Berge FR, et al
    From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
    BMC Cancer. 2024;24:662.
    >> Share

  26. CHRISTAKOUDI S, Tsilidis KK, Riboli E
    Prospective associations of leucocyte subtypes and obesity with the risk of developing cutaneous malignant melanoma in the UK Biobank cohort.
    BMC Cancer. 2024;24:625.
    >> Share

  27. JANSSEN JC, van Dijk B, de Joode K, Aarts MJB, et al
    Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    BMC Cancer. 2024;24:632.
    >> Share

  28. MIAO L, Miao T, Zhang Y, Hao J, et al
    Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
    BMC Cancer. 2024;24:602.
    >> Share

    April 2024
  29. ZHANG Y, Zheng J, Chen M, Zhao S, et al
    Modulating DNA damage response in uveal melanoma through embryonic stem cell microenvironment.
    BMC Cancer. 2024;24:519.
    >> Share

  30. SHENG M, Sun R, Fu J, Lu G, et al
    The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    BMC Cancer. 2024;24:399.
    >> Share

    March 2024
  31. WHITMAN ED, Totev TI, Jiang S, da Costa WL Jr, et al
    Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
    BMC Cancer. 2024;24:389.
    >> Share

  32. NEVAKIVI R, Siiskonen H, Haimakainen S, Harvima IT, et al
    Spectrum of malignant and premalignant skin lesions in 505 adult subjects at risk of skin cancers.
    BMC Cancer. 2024;24:338.
    >> Share

    February 2024
  33. ZHU Z, Wang W, Zha Y, Wang X, et al
    Development and validation of a nomogram for predicting overall survival in patients with sinonasal mucosal melanoma.
    BMC Cancer. 2024;24:184.
    >> Share

    January 2024
  34. SAAMARTHY K, Ahlqvist K, Daams R, Balagunaseelan N, et al
    Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells.
    BMC Cancer. 2024;24:103.
    >> Share

  35. WANG X, Li J, Li Y, Lv M, et al
    Single-cell analysis of the cellular landscape of vulvar melanoma provides new insight for immunotherapy administration.
    BMC Cancer. 2024;24:101.
    >> Share

    November 2023
  36. TSAKMAKLIS A, Farowski F, Zenner R, Lesker TR, et al
    TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
    BMC Cancer. 2023;23:1160.
    >> Share

  37. ZHAO Y, Amorrortu RP, Stewart SC, Ghia KM, et al
    Melanoma and CLL co-occurrence and survival: role of KC history.
    BMC Cancer. 2023;23:1084.
    >> Share

    October 2023
  38. LI L, Pei B, Feng Y
    Exogenous hormone therapy and non-melanoma skin cancer (keratinocyte carcinoma) risk in women: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:946.
    >> Share

    September 2023
  39. JOSHY G, Khalatbari-Soltani S, Soga K, Butow P, et al
    Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
    BMC Cancer. 2023;23:774.
    >> Share

    August 2023
  40. LIU J, Luo B, Zhang P, Jiang K, et al
    Necroptosis-related LncRNAs in skin cutaneous melanoma: evaluating prognosis, predicting immunity, and guiding therapy.
    BMC Cancer. 2023;23:752.
    >> Share

    July 2023
  41. OLATEJU OA, Zeng Z, Thornton JD, Mgbere O, et al
    Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
    BMC Cancer. 2023;23:655.
    >> Share

    June 2023
  42. LIU W, Ji Y, Wang F, Li C, et al
    Morusin shows potent antitumor activity for melanoma through apoptosis induction and proliferation inhibition.
    BMC Cancer. 2023;23:602.
    >> Share

  43. GEOFFROIS L, Harle A, Sahki N, Sikanja A, et al
    Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
    BMC Cancer. 2023;23:554.
    >> Share

  44. LI H, Sun X, Zhao Y, Zhang C, et al
    Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
    BMC Cancer. 2023;23:528.
    >> Share

    May 2023
  45. DIETSCH B, Weller C, Sticht C, de la Torre C, et al
    Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern.
    BMC Cancer. 2023;23:436.
    >> Share

  46. WU N, Sun H, Sun Q, Zhang F, et al
    Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:414.
    >> Share

  47. GRAVIS G, Marino P, Olive D, Penault-LLorca F, et al
    A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
    BMC Cancer. 2023;23:393.
    >> Share

  48. LIU J, Pei S, Zhang P, Jiang K, et al
    Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma.
    BMC Cancer. 2023;23:388.
    >> Share

    April 2023
  49. TANG W, Shao Q, He Z, Zhang X, et al
    Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis.
    BMC Cancer. 2023;23:303.
    >> Share

  50. REZAIE Y, Fattahi F, Mashinchi B, Kamyab Hesari K, et al
    High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients.
    BMC Cancer. 2023;23:302.
    >> Share

    March 2023
  51. SUN S, Deng M, Wen J, Chen X, et al
    Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
    BMC Cancer. 2023;23:292.
    >> Share

  52. KAMMINGA NCW, Wakkee M, De Bruin RJ, van der Veldt AAM, et al
    Oncological healthcare providers' perspectives on appropriate melanoma survivorship care: a qualitative focus group study.
    BMC Cancer. 2023;23:278.
    >> Share

  53. HERRSPIEGEL C, Plastino F, Lardner E, Seregard S, et al
    A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival.
    BMC Cancer. 2023;23:277.
    >> Share

  54. JOHNSON DB, Atkins MB, Hennessy C, Wise-Draper T, et al
    Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
    BMC Cancer. 2023;23:265.
    >> Share

  55. SHEN Y, Li M, Liao L, Gao S, et al
    Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients.
    BMC Cancer. 2023;23:242.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016